Antitumor Effect of Somatostatin Analogs in Neuroendocrine Tumors

被引：6
|
作者：
Chua, Yu Jo [1 ]
Michael, Michael [2 ]
Zalcberg, John R. [2 ]
Hicks, Rod J. [3 ]
Goldstein, David [4 ]
Liauw, Winston [5 ]
Price, Timothy [6 ]
机构：
[1] Canberra Hosp, Med Oncol Unit, Canberra, ACT, Australia
[2] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Australia
[3] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Australia
[4] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW 2031, Australia
[5] St George Hosp, Canc Care Ctr, Kogarah, NSW, Australia
[6] Queen Elizabeth Hosp, Dept Oncol, Woodville, SA 5011, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 03期
关键词：
D O I：
10.1200/JCO.2009.26.0612
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E41 / E42
页数：2
相关论文
共 50 条
  • [31] Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Toumpanakis, Christos
    Caplin, Martyn E.
    SEMINARS IN ONCOLOGY, 2013, 40 (01) : 56 - 68
  • [32] Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors
    Hasskarl, Jens
    Kaufmann, Martina
    Schmid, Herbert A.
    FUTURE ONCOLOGY, 2011, 7 (07) : 895 - 913
  • [33] Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives
    Baldelli, Roberto
    Barnabei, A.
    Rizza, L.
    Isidori, A. M.
    Rota, F.
    Di Giacinto, P.
    Paoloni, A.
    Torino, F.
    Corsello, S. M.
    Lenzi, A.
    Appetecchia, M.
    FRONTIERS IN ENDOCRINOLOGY, 2014, 5
  • [34] Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors
    Kvols, Larry K.
    Woltering, Eugene A.
    ANTI-CANCER DRUGS, 2006, 17 (06) : 601 - 608
  • [35] Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
    Öberg, K
    Kvols, L
    Caplin, M
    Delle Fave, G
    de Herder, W
    Rindi, G
    Ruszniewski, P
    Woltering, EA
    Wiedenmann, B
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 966 - 973
  • [36] Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
    William H. Ludlam
    Lowell Anthony
    Advances in Therapy, 2011, 28 : 825 - 841
  • [37] Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors
    Santo, Giulia
    di Santo, Gianpaolo
    Cicone, Francesco
    Virgolini, Irene
    JOURNAL OF NEUROENDOCRINOLOGY, 2025, 37 (03)
  • [38] Adjuvant therapy with somatostatin analogs for recurrent gastric neuroendocrine tumors type 1
    Markovich, Alla Anatolievna
    Zhulikov, Yaroslav
    Evdokimova, Ekaterina
    Gorbunova, Vera
    Emelianova, Galina
    Gadzhieva, Kizler
    Malikhova, Olga
    Karasev, Ivan
    Delektorskaya, Vera
    Kuvshinov, Yuri
    Kuznetsova, Anna
    Artamonova, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 665 - 665
  • [39] The Drawback to Treat Neuroendocrine Bronchial Tumors with High Doses of Radiolabelled Somatostatin Analogs
    Limouris, G. S.
    Karfis, I.
    Paphiti, M. I.
    McCready, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S457 - S457
  • [40] Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
    Imam, H
    Eriksson, B
    Lukinius, A
    Janson, ET
    Lindgren, PG
    Wilander, E
    Oberg, K
    ACTA ONCOLOGICA, 1997, 36 (06) : 607 - 614
12345